An investigation of biomarkers derived from legacy microarray data for their utility in the RNA-seq era

Table 1 Definition of the clinical endpoints for the 498 SEQC NB samples and the 175 AML samples

Endpoint category	Data set	Total samples(n)	Endpoint	Training set			Validation set
Endpoint category	Data set	Total samples(n)	Endpoint	Samples(n)	1	0	Samples(n)	1	0
Binary (1/0)	SEQC NB	498	A_EFS_All (event, yes/no)	249	89	160	249	94	155
			B_OS_All (death, yes/no)	249	51	198	249	54	195
			C_SEX_All (female/male)	249	103	146	249	108	141
		272	D_FAV_All (unfavorable/favorable)	136	45	91	136	46	90
		176	E_EFS_HR (event, yes/no)	86	55	31	90	65	25
		176	F_OS_HR (death, yes/no)	86	43	43	90	49	41
	AML	175	Sex (female/male)	89	43	46	86	39	47
	AML	175	Cytogenetic risk (poor/good)	89	72	17	86	70	16
Continuous (time)	SEQC NB	498	A_EFS_All (event, days)	249			249
		498	B_OS_All (death, days)	249			249
		176	E_EFS_HR (event, days)	86			90
		176	F_OS_HR (death, days)	86			90
	AML	175	EFS (event, months)	89			86
	AML	175	OS (death, months)	89			86

EFS: Event-free survival; FAV: Unfavorable/Favorable (class label for extreme disease course); HR: High-risk patients; OS: Overall survival.

ISSN: 1474-760X